eGlaxoSmithKline

As per our previous discussion, there is little doubt anymore but that our HIV / AIDS drugs are well positioned to go to the next level of modern emergent medicine. Whatever treatment modalities that will arise in the future will be ICT-based (Information Communication Technology) and will be executed in practice utilizing mHealth (mobile) practices that are part of a network of eCare (electronic), eServices, eSurvellience and eLearning structures (Sorenson et al., 2008). The past prediction appears accurate that by this year (2012), half of all people in remote but developing areas of the world will have access to mobile technology (Singh, nd). It is therefore incumbent upon GlaxoSmithKline (GSK) to establish itself as a leader in facilitating how these efforts can complement our pharmaceuticals interventions, particularly since it is now well accepted that antiretroviral interventions are the only known approach for slowing the disease progression in infected individuals....
[ View Full Essay]